FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to pharmacology and medicine and aims at prevention of pneumonia. For preventing pneumonia, a medicinal agent containing a hexapeptide of formula H-Tyr-D-Ala-Gly-Phe-Leu-Arg-OH or its pharmaceutically acceptable salt are used.
EFFECT: use of the invention provides prevention of developing pneumonia and reduced risk of adverse consequences of developing pneumonia, including a reduced risk of mortality from pneumonia.
1 cl, 2 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME BY DALARGIN AND A PULMONARY SURFACTANT | 2020 |
|
RU2728821C1 |
| STABLE AQUEOUS PHARMACEUTICAL COMPOSITION FOR INHALATIONS CONTAINING A HEXAPEPTIDE | 2020 |
|
RU2739573C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION IN THE FORM OF A SUPPOSITORY CONTAINING HEXAPEPTIDE | 2020 |
|
RU2737800C1 |
| METHOD FOR TREATMENT OF LUNG DISEASES BY INHALATION ADMINISTRATION OF MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2770364C1 |
| MEANS AND METHOD FOR PREVENTION OF INTERSTITIAL PNEUMONIA OF INFECTIOUS ETIOLOGY | 2021 |
|
RU2784177C1 |
| MEANS FOR PREVENTION OF INTERSTITIAL PNEUMONIA | 2020 |
|
RU2747550C1 |
| BIOMEDICAL CELL PRODUCT BASED ON MAMMALIAN MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2781968C1 |
| USE OF HEXAPEPTIDE TO REDUCE LEVELS OF EXTRACELLULAR HMGB1 PROTEIN IN INFLAMMATORY DISEASES | 2021 |
|
RU2813878C2 |
